Literature DB >> 2783455

Imaging of brain tumors with L-3-[123I]iodo-alpha-methyl tyrosine and SPECT.

H J Biersack1, H H Coenen, G Stöcklin, K Reichmann, A Bockisch, P Oehr, M Kashab, O Rollmann.   

Abstract

Carbon-11-labeled amino acids have been successfully used to image brain tumors by PET. This study was undertaken to evaluate the potential of L-3-[123I]-iodo-alpha-methyl tyrosine (123IMT) for metabolic imaging of brain tumors. Ten patients (glioblastoma, oligodendroglioma, lymphoma, and metastases) had early and delayed brain SPECT with a rotating gamma camera after i.v.-injection of 200-300 MBq 123IMT. In nine patients the tumors showed intense uptake of the radiotracer. Tumor-to-brain tissue ratios were between 1.4 and 2.6. 123IMT shows potentials for monitoring the effects of brain tumor therapy.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2783455

Source DB:  PubMed          Journal:  J Nucl Med        ISSN： 0161-5505            Impact factor:   10.057


  16 in total

1.  The history of 123-iodo-methyl tyrosine.

Authors:  H J Biersack
Journal:  Eur J Nucl Med       Date:  2001-03

2.  Value of 123I-IMT SPECT for diagnosis of recurrent non-astrocytic intracranial tumours.

Authors:  Michail Plotkin; Holger Amthauer; Julia Eisenacher; Reinhard Wurm; Roger Michel; Peter Wust; Florian Stockhammer; Rainer Röttgen; Matthias Gutberlet; Juri Ruf; Roland Felix
Journal:  Neuroradiology       Date:  2005-01-04       Impact factor: 2.804

Review 3.  Tracers for metabolic imaging of brain and heart. Radiochemistry and radiopharmacology.

Authors:  G Stöcklin
Journal:  Eur J Nucl Med       Date:  1992

4.  Synthesis, radiolabeling, and biological evaluation of (R)- and (S)-2-amino-3-[(18)F]fluoro-2-methylpropanoic acid (FAMP) and (R)- and (S)-3-[(18)F]fluoro-2-methyl-2-N-(methylamino)propanoic acid (NMeFAMP) as potential PET radioligands for imaging brain tumors.

Authors:  Weiping Yu; Jonathan McConathy; Larry Williams; Vernon M Camp; Eugene J Malveaux; Zhaobin Zhang; Jeffrey J Olson; Mark M Goodman
Journal:  J Med Chem       Date:  2010-01-28       Impact factor: 7.446

5.  Can nuclear medicine predict response to chemotherapy?

Authors:  J L Moretti; M Caglar; M Duran-Cordobes; J F Morere
Journal:  Eur J Nucl Med       Date:  1995-02

6.  Validation of brain tumour imaging with p-[123I]iodo-L-phenylalanine and SPECT.

Authors:  Dirk Hellwig; Ralf Ketter; Bernd F M Romeike; Nadja Sell; Andrea Schaefer; Jean R Moringlane; Carl-Martin Kirsch; Samuel Samnick
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-05-18       Impact factor: 9.236

Review 7.  The role of nuclear medicine in oncology.

Authors:  H J Biersack; B Briele; A L Hotze; P Oehr; L Qian; M A Mekkawy; W J Shih
Journal:  Ann Nucl Med       Date:  1992-08       Impact factor: 2.668

8.  Multivariate analysis of clinical prognostic factors in patients with glioblastoma multiforme treated with a combined modality approach.

Authors:  Branislav Jeremic; Biljana Milicic; Danica Grujicic; Aleksandar Dagovic; Jasna Aleksandrovic
Journal:  J Cancer Res Clin Oncol       Date:  2003-07-15       Impact factor: 4.553

9.  Diagnostics of cerebral gliomas with radiolabeled amino acids.

Authors:  Karl-Josef Langen; Klaus Tatsch; Anca-Ligia Grosu; Andreas H Jacobs; Matthias Weckesser; Osama Sabri
Journal:  Dtsch Arztebl Int       Date:  2008-01-25       Impact factor: 5.594

10.  Uptake of iodine-123-alpha-methyl tyrosine by gliomas and non-neoplastic brain lesions.

Authors:  T Kuwert; C Morgenroth; B Woesler; P Matheja; S Palkovic; B Vollet; S Samnick; U Maasjosthusmann; H Lerch; F J Gildehaus; H Wassmann; O Schober
Journal:  Eur J Nucl Med       Date:  1996-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.